Vericel Co. (NASDAQ:VCEL) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 7.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 578,712 shares of the biotechnology company’s stock after selling 44,915 shares during the quarter. Victory Capital Management Inc.’s holdings in Vericel were worth $31,777,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Arcadia Investment Management Corp MI acquired a new stake in Vericel during the 4th quarter worth $48,000. Farther Finance Advisors LLC boosted its position in shares of Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 405 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 1,058 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Vericel during the 3rd quarter valued at about $92,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of Vericel by 826.6% during the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock valued at $138,000 after acquiring an additional 2,240 shares during the last quarter.

Vericel Price Performance

NASDAQ VCEL opened at $49.56 on Monday. The firm’s 50-day moving average is $56.48 and its two-hundred day moving average is $51.98. Vericel Co. has a 12 month low of $39.12 and a 12 month high of $63.00. The stock has a market capitalization of $2.48 billion, a P/E ratio of 826.14 and a beta of 1.78.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. BTIG Research boosted their price target on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Truist Financial reissued a “buy” rating and set a $61.00 price target (down previously from $67.00) on shares of Vericel in a research report on Monday, March 3rd. Stephens reissued an “overweight” rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Finally, Canaccord Genuity Group boosted their price target on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.29.

Insider Buying and Selling at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now directly owns 26,595 shares in the company, valued at $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Siegal sold 1,092 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the sale, the insider now owns 1,206 shares in the company, valued at $74,759.94. This trade represents a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 7,500 shares of company stock valued at $466,200 over the last 90 days. 5.20% of the stock is owned by insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.